, Leishmaniasis. Lancet, vol.392, pp.951-970, 2018.
Human African trypanosomiasis, Lancet, vol.2017, pp.2397-2409, 10110. ,
URL : https://hal.archives-ouvertes.fr/hal-02322417
, Lancet, vol.391, pp.82-94, 2018.
Overcoming neglect of kinetoplastid diseases, Science, vol.348, issue.6238, pp.974-976, 2015. ,
New class of antitrypanosomal agents based on imidazopyridines, ACS Med. Chem. Lett, vol.2017, issue.7, pp.766-770 ,
Novel aminoquinoline derivatives significantly reduce parasite load in Leishmania infantum infected mice, ACS Med. Chem. Lett, vol.2018, issue.7, pp.629-634 ,
Antiparasitic lead discovery: toward optimization of a chemotype with activity against multiple protozoan parasites, ACS Med. Chem. Lett, vol.2017, issue.3, pp.350-354 ,
Oral fexinidazole for human African trypanosomiasis, Lancet, vol.391, pp.100-102, 2018. ,
The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis, vol.5, 2016. ,
Current and future prospects of nitro-compounds as drugs for trypanosomiasis and leishmaniasis, Curr. Med. Chem ,
An essential type I nitroreductase from Leishmania major can be used to activate leishmanicidal prodrugs, J. Biol. Chem, issue.40, pp.28466-28476, 2013. ,
The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis, Sci. Transl. Med, vol.2012, issue.119, pp.119-120 ,
Assessing the essentiality of Leishmania donovani nitroreductase and its role in nitro drug activation, Antimicrob. Agents Chemother, vol.57, issue.2, pp.901-906, 2013. ,
Activation of bicyclic nitro-drugs by a novel nitroreductase (NTR2) in Leishmania, PLoS Pathog, vol.12, issue.11, 2016. ,
The R enantiomer of the antitubercular drug PA-824 as a potential oral treatment for visceral leishmaniasis, Antimicrob. Agents Chemother, vol.2013, issue.10, pp.4699-4706 ,
Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation, Antimicrob. Agents Chemother, vol.56, issue.1, pp.115-123, 2012. ,
Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites, J. Biol. Chem, issue.15, pp.13088-13095, 2011. ,
Targeting the human parasite Leishmania donovani: Discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series, Bioorg. Med. Chem, vol.21, issue.22, pp.7155-7164, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-01460446
Vanelle, P. 8-Aryl-6-chloro-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridines as potent antitrypanosomatid molecules bioactivated by type 1 nitroreductases, Eur. J. Med. Chem, vol.157, pp.115-126, 2018. ,
Azas, N. 4-Thiophenoxy-2-trichloromethyquinazolines display in vitro selective antiplasmodial activity against the human malaria parasite Plasmodium falciparum, Bioorg. Med. Chem. Lett, issue.19, pp.6003-6006, 2011. ,
Looking for new antileishmanial derivatives in 8-nitroquinolin-2(1H)-one series, Eur. J. Med. Chem, vol.92, pp.282-294, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01460569
The activity of fexinidazole (HOE 239) against experimental infections with Trypanosoma cruzi, trichomonads and Entamoeba histolytica, Ann. Trop. Med. Parasitol, vol.77, issue.1, pp.13-26, 1983. ,
Entamoeba and Trichomonas enzymes activate metronidazole (nitroreductases) and inactivate metronidazole (nitroimidazole reductases), Antimicrob. Agents Chemother, vol.53, issue.2, pp.458-464, 2009. ,
Detection of carcinogens as mutagens: bacterial tester strains with R factor plasmids, Proc. Natl. Acad. Sci. U. S. A, vol.72, issue.3, pp.979-983, 1975. ,
Structural alterations that differentially affect the mutagenic and antitrichomonal activities of 5-nitroimidazoles, J. Med. Chem, vol.30, issue.1, pp.150-156, 1987. ,
Relative importance of bacterial and mammalian nitroreductases for niridazole mutagenesis, Cancer Res, vol.40, issue.12, pp.4599-4605, 1980. ,
Nitroreductase from Salmonella typhimurium: characterization and catalytic activity, Org. Biomol. Chem, vol.8, issue.8, pp.1826-1832, 2010. ,
Genotoxicity profile of fexinidazole, a drug candidate in clinical development for human African trypanomiasis (sleeping sickness), Mutagenesis, vol.2012, issue.5, pp.523-532 ,
Hit and lead criteria in drug discovery for infectious diseases of the developing world, Nat. Rev. Drug Discovery, vol.14, issue.11, pp.751-758, 2015. ,
The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery, Nat. Rev. Drug Discovery, vol.2010, issue.12, pp.929-939 ,